Literature DB >> 23835929

The association between pro-inflammatory cytokines, regional cerebral metabolism, and cognitive complaints following adjuvant chemotherapy for breast cancer.

K L Pomykala1, P A Ganz, J E Bower, L Kwan, S A Castellon, S Mallam, I Cheng, R Ahn, E C Breen, M R Irwin, D H S Silverman.   

Abstract

To examine relationships following adjuvant chemotherapy between circulating pro-inflammatory cytokines, regional cerebral metabolism, and cognitive complaints in early stage breast cancer patients. 33 breast cancer patients who had completed initial treatment (surgery, ± radiation, 23 chemotherapy, 10 no chemotherapy) obtained resting (18)F-FDG PET/CT brain imaging at baseline and 1 year later. Pro-inflammatory cytokine markers (IL-1ra, sTNF-RII, CRP, and IL-6) and cognitive complaints were also assessed at both time points. At baseline, consistent correlations were seen between the left medial frontal and right inferior lateral anterior temporal cortices and inflammatory markers within the chemotherapy group, and not in the no chemotherapy group. After 1 year, correlations persisted in the medial frontal cortex and the temporal cortex, the latter shifting superiorly. Both of these regional correlations demonstrated the highest levels of significance when looking across the 1 year time frame (IL-1ra: peak voxel p < 0.0005; cluster size p < 0.0005, p = 0.001 after correction (medial prefrontal), p < 0.0005; cluster size p = 0.001, p = 0.029 corr. (anterior temporal), sTNF-RII: p < 0.0005; cluster size p = 0.001, p = 0.040 corr. (medial prefrontal)). Positive correlations were also seen within the chemotherapy group between baseline memory complaints and the medial frontal (p < 0.0005; cluster size p < 0.0005, p < 0.0005 corr.) and anterior temporal (p < 0.0005; cluster size p < 0.0005, p = 0.002 corr.) cortices at baseline and 1 year later. Metabolism in the medial prefrontal cortex and anterior temporal cortex was found to correlate with both memory complaints and cytokine marker levels in chemotherapy patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23835929      PMCID: PMC4399818          DOI: 10.1007/s11682-013-9243-2

Source DB:  PubMed          Journal:  Brain Imaging Behav        ISSN: 1931-7557            Impact factor:   3.978


  52 in total

1.  Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma.

Authors:  Tim A Ahles; Andrew J Saykin; Charlotte T Furstenberg; Bernard Cole; Leila A Mott; Karen Skalla; Marie B Whedon; Sarah Bivens; Tara Mitchell; E Robert Greenberg; Peter M Silberfarb
Journal:  J Clin Oncol       Date:  2002-01-15       Impact factor: 44.544

2.  Alterations in brain activation during working memory processing associated with breast cancer and treatment: a prospective functional magnetic resonance imaging study.

Authors:  Brenna C McDonald; Susan K Conroy; Tim A Ahles; John D West; Andrew J Saykin
Journal:  J Clin Oncol       Date:  2012-06-04       Impact factor: 44.544

Review 3.  Interferon-α (IFNα) neurotoxicity.

Authors:  Cari Fritz-French; William Tyor
Journal:  Cytokine Growth Factor Rev       Date:  2012-02-17       Impact factor: 7.638

4.  Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, depression, and sleep disturbance share a common underlying mechanism?

Authors:  Julienne E Bower; Patricia A Ganz; Michael R Irwin; Lorna Kwan; Elizabeth C Breen; Steve W Cole
Journal:  J Clin Oncol       Date:  2011-08-08       Impact factor: 44.544

5.  A serum protein-based algorithm for the detection of Alzheimer disease.

Authors:  Sid E O'Bryant; Guanghua Xiao; Robert Barber; Joan Reisch; Rachelle Doody; Thomas Fairchild; Perrie Adams; Steven Waring; Ramon Diaz-Arrastia
Journal:  Arch Neurol       Date:  2010-09

6.  Interleukin-6 covaries inversely with cognitive performance among middle-aged community volunteers.

Authors:  Anna L Marsland; Karen L Petersen; Rama Sathanoori; Matthew F Muldoon; Serina A Neumann; Christopher Ryan; Janine D Flory; Stephen B Manuck
Journal:  Psychosom Med       Date:  2006 Nov-Dec       Impact factor: 4.312

7.  Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer.

Authors:  Nadine Tchen; Helen G Juffs; Fiona P Downie; Qi-Long Yi; Hanxian Hu; Irene Chemerynsky; Mark Clemons; Michael Crump; Paul E Goss; David Warr; Mary E Tweedale; Ian F Tannock
Journal:  J Clin Oncol       Date:  2003-11-15       Impact factor: 44.544

8.  Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment.

Authors:  Barbara Collins; Joyce Mackenzie; Angela Stewart; Catherine Bielajew; Shailendra Verma
Journal:  Psychooncology       Date:  2009-02       Impact factor: 3.894

9.  Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve.

Authors:  Tim A Ahles; Andrew J Saykin; Brenna C McDonald; Yuelin Li; Charlotte T Furstenberg; Brett S Hanscom; Tamsin J Mulrooney; Gary N Schwartz; Peter A Kaufman
Journal:  J Clin Oncol       Date:  2010-09-13       Impact factor: 44.544

Review 10.  Neuropsychological dysfunction associated with cancer and cancer therapies: a conceptual review of an emerging target.

Authors:  J S Wefel; A E Kayl; C A Meyers
Journal:  Br J Cancer       Date:  2004-05-04       Impact factor: 7.640

View more
  51 in total

Review 1.  Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors.

Authors:  M Lange; F Joly; J Vardy; T Ahles; M Dubois; L Tron; G Winocur; M B De Ruiter; H Castel
Journal:  Ann Oncol       Date:  2019-12-01       Impact factor: 32.976

2.  Cognitive function after the initiation of adjuvant endocrine therapy in early-stage breast cancer: an observational cohort study.

Authors:  Patricia A Ganz; Laura Petersen; Steven A Castellon; Julienne E Bower; Daniel H S Silverman; Steven W Cole; Michael R Irwin; Thomas R Belin
Journal:  J Clin Oncol       Date:  2014-09-29       Impact factor: 44.544

Review 3.  Chemobrain: a critical review and causal hypothesis of link between cytokines and epigenetic reprogramming associated with chemotherapy.

Authors:  Xiao-Min Wang; Brian Walitt; Leorey Saligan; Agnes F Y Tiwari; Chi Wai Cheung; Zhang-Jin Zhang
Journal:  Cytokine       Date:  2015-01-05       Impact factor: 3.861

4.  Neuroimaging biomarkers and cognitive function in non-CNS cancer and its treatment: current status and recommendations for future research.

Authors:  Andrew J Saykin; Michiel B de Ruiter; Brenna C McDonald; Sabine Deprez; Daniel H S Silverman
Journal:  Brain Imaging Behav       Date:  2013-12       Impact factor: 3.978

5.  Links between inflammation, amygdala reactivity, and social support in breast cancer survivors.

Authors:  Keely A Muscatell; Naomi I Eisenberger; Janine M Dutcher; Steven W Cole; Julienne E Bower
Journal:  Brain Behav Immun       Date:  2015-09-15       Impact factor: 7.217

6.  Systematic review of self-reported cognitive function in cancer patients following chemotherapy treatment.

Authors:  Victoria J Bray; Haryana M Dhillon; Janette L Vardy
Journal:  J Cancer Surviv       Date:  2018-05-04       Impact factor: 4.442

7.  Identifying cytokine predictors of cognitive functioning in breast cancer survivors up to 10 years post chemotherapy using machine learning.

Authors:  Ashley M Henneghan; Oxana Palesh; Michelle Harrison; Shelli R Kesler
Journal:  J Neuroimmunol       Date:  2018-04-19       Impact factor: 3.478

Review 8.  Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults.

Authors:  Jeffrey S Wefel; Shelli R Kesler; Kyle R Noll; Sanne B Schagen
Journal:  CA Cancer J Clin       Date:  2014-12-05       Impact factor: 508.702

Review 9.  Chemotherapy-related cognitive impairment in older patients with cancer.

Authors:  Kah Poh Loh; Michelle C Janelsins; Supriya G Mohile; Holly M Holmes; Tina Hsu; Sharon K Inouye; Meghan S Karuturi; Gretchen G Kimmick; Stuart M Lichtman; Allison Magnuson; Mary I Whitehead; Melisa L Wong; Tim A Ahles
Journal:  J Geriatr Oncol       Date:  2016-07-05       Impact factor: 3.599

Review 10.  Disease drivers of aging.

Authors:  Richard J Hodes; Felipe Sierra; Steven N Austad; Elissa Epel; Gretchen N Neigh; Kristine M Erlandson; Marissa J Schafer; Nathan K LeBrasseur; Christopher Wiley; Judith Campisi; Mary E Sehl; Rosario Scalia; Satoru Eguchi; Balakuntalam S Kasinath; Jeffrey B Halter; Harvey Jay Cohen; Wendy Demark-Wahnefried; Tim A Ahles; Nir Barzilai; Arti Hurria; Peter W Hunt
Journal:  Ann N Y Acad Sci       Date:  2016-12       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.